Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology, Fibrosis, and ER Stress Research.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for PDIA3 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PDIA3 Recombinant Protein High purity (>95%), Endotoxin <1.0 EU/μg. Sequence Verified. HEK293 expressed for native folding. |
View PDIA3 Products |
| Gene Delivery | PDIA3 Promise-ORF / Lentivirus Full-length ORF for stable cell lines and translocation studies. |
View PDIA3 Products |
| Benchmark Ab | Anti-PDIA3 Recombinant Antibody Recombinant positive control for surface staining and functional block. |
View PDIA3 Products |
| Validator | PDIA3 siRNA Set For knockdown verification in target specificity assays. |
View PDIA3 Products |
| Related Target A | CALR (Calreticulin) Co-chaperone that forms a functional complex with PDIA3 in the ER and on the cell surface during ICD. |
View CALR Products |
| Related Target B | PDIA1 (PDI) Crucial homolog for counter-screening to ensure drug selectivity and avoid off-target toxicity. |
View PDIA1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Subfamily counter-screening (PDIA3 vs. PDIA1 selectivity) | Highly purified, sequence-verified recombinant PDIA3 and PDIA1 proteins available (>95% purity by SDS-PAGE). |
| Assessing protein-protein interaction (PPI) inhibition | HEK293 expressed PDIA3 and Calreticulin (CALR) preserving native post-translational modifications. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity and target knockdown checks |
Live PDIA3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PDIA3 therapeutics is intensifying, with major players shifting focus from broad-spectrum endoplasmic reticulum stress modulators to targeted monoclonal antibodies and selective small molecules. As first-generation therapies targeting the calreticulin/PDIA3 complex reach the clinic, the next wave of R&D is targeting cell-surface translocated PDIA3 (csPDIA3) to selectively induce immunogenic cell death (ICD) in solid tumors and inhibit platelet aggregation in cardiovascular diseases without disrupting systemic ER homeostasis.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic Institutes, Biotech Startups | Glioblastoma, Airway Fibrosis | Selectivity Assay (Need Mutant vs WT Proteins and PDIA1 counter-screen) |
| Monoclonal Antibodies | Biopharma Innovators | Thrombosis, Solid Tumors | Surface Binding & Translocation Assay (Need Lentivirus for Stable Cell Lines) |
| Combination Therapies (ICD Inducers) | Oncology Consortia | Refractory Cancers | Protein-Protein Interaction Blockade (Need high-purity PDIA3 and CALR) |